Close Menu

Breaking News

The French firm attributed the revenue increase to strong sales of its theranostics products, which include its therapeutic drug monitoring tests.

The Chinese incubator will be in the tradition of Illumina's Bay Area and Cambridge, UK-based Accelerator programs that invest in genomics startups.

News items for the week of Jan. 25, 2021. 

Qualifying children will have free access to Invitae's Comprehensive Deafness Panel, which assesses multiple genes linked to syndromic and non-syndromic deafness.

The company cited its revenue increase to high demand for its SARS-CoV-2 testing products and the acquisition of a PCR instrument manufacturing partner.

The firm plans to use the net proceeds for general corporate purposes, including working capital and capital expenditures.

The study's findings could also point to potential treatment candidates for post-traumatic stress disorder, the researchers said.

Starting with a search for genetic factors linked to brain protein levels, investigators identified 11 candidate genes that may be causal in Alzheimer's disease.

MicroGem is developing a PCR-based SARS-CoV-2 saliva test designed to detect SARS-CoV-2 at the point-of-care with results in 15 minutes.

The diagnostic is composed of Agilent's Bravo automation workstation and Mammoth's DETECTR BOOST SARS-CoV-2 assay.

The company will use the proceeds to commercialize and further develop its Proteograph Product Suite and for other R&D and corporate purposes.

The Phase II trial will use OmniSeq's RNA-seq assay to determine whether patients should be treated with one of two agents combined with BMS' nivolumab.

The device also has Emergency Use Authorization from the US Food and Drug Administration and has CE marking for in vitro diagnostic use.

DNA Script will build a prototype qPCR probe manufacturing platform that can be used in the rapid development of biothreat diagnostics.

The company's life sciences revenues grew 76 percent, while diagnostics revenues increased 24 percent.

Within its diagnostics division, the firm posted molecular diagnostics revenue of $995.3 million, up more than fivefold from $178.5 million in fiscal Q1 2020.

The study, which showed that the disease may not only result from tobacco exposure as previously thought, could lay the groundwork for targeted therapies.

The partners will offer an end-to-end microbiome sequencing and analysis service through Transnetyx's global network of model organism research customers.

Using available genetic data, the researchers also found that dairy consumption in the region appears to predate the expansion of lactase persistence.

Tempus has been providing Bristol Myers Squibb with de-identified transcriptomic datasets to help in the identification of new cancer biomarkers.

The company is selling more than 3.9 million shares at $38 per share and has offered underwriters an option to add additional shares under the same terms.

The two California firms are linking their bioinformatics platforms in hopes of accelerating biomarker and drug discovery processes for pharma companies.

The San Diego-based company said it plans to use the funds to speed development of its ProteoCode proteomics platform.


Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.